ISL/LEN

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Safety and EfficacyHIV-1Tenofovir

130 competitors in Safety and Efficacy

#DrugCompanyPhaseTrials

1

Avastin

Roche

Phase 3

32

Actemra

Roche

Phase 3

13

Humira

RRanbaxy Laboratories Limited

Phase 3

34

Rayos

RRoxane Laboratories

Phase 3

35

Empaveli

Apellis Pharmaceuticals

Phase 3

26

CAB LA

GSK

Phase 3

17

B/F/TAF

Gilead

Phase 3

58

Nuzyra

PParatek Pharmaceuticals Inc

Phase 3

19

Tepadina

Jazz Pharmaceuticals

Phase 2

110

Bomedemstat

Merck & Co.

Phase 3

1Show 37 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Safety and Efficacy1 trial

Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV

Active, not recruiting·Gilead·Phase 2·NCT05052996·142 enrolled

HIV-11 trial

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1

Active, not recruiting·Gilead·Phase 3·NCT06630299·600 enrolled

Tenofovir1 trial

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1

Active, not recruiting·Gilead·Phase 3·NCT06630286·609 enrolled

Details

Drug Info

Related News